MX368261B - Letalidad sintetica y el tratamiento de cancer. - Google Patents
Letalidad sintetica y el tratamiento de cancer.Info
- Publication number
- MX368261B MX368261B MX2014000661A MX2014000661A MX368261B MX 368261 B MX368261 B MX 368261B MX 2014000661 A MX2014000661 A MX 2014000661A MX 2014000661 A MX2014000661 A MX 2014000661A MX 368261 B MX368261 B MX 368261B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- synthetic lethality
- methods
- subject
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 231100000225 lethality Toxicity 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102100028085 Glycylpeptide N-tetradecanoyltransferase 1 Human genes 0.000 abstract 1
- 102100023122 Glycylpeptide N-tetradecanoyltransferase 2 Human genes 0.000 abstract 1
- 101000979544 Homo sapiens Glycylpeptide N-tetradecanoyltransferase 2 Proteins 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
La presente invención se refiere a compuestos, composiciones y métodos para el tratamiento de cáncer. También se describen métodos y usos para identificar sujetos con cáncer que son apropiados para tratamientos con los compuestos, composición y métodos son descritos en la presente. En un aspecto de la presente invención, se provee un método de tratamiento de un sujeto que tiene cáncer deficiente de NMT2, que comprende administrar al sujeto un inhibidor de NMT.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161510686P | 2011-07-22 | 2011-07-22 | |
PCT/CA2012/000696 WO2013013302A1 (en) | 2011-07-22 | 2012-07-23 | Synthetic lethality and the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014000661A MX2014000661A (es) | 2014-09-08 |
MX368261B true MX368261B (es) | 2019-09-25 |
Family
ID=47600415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014000661A MX368261B (es) | 2011-07-22 | 2012-07-23 | Letalidad sintetica y el tratamiento de cancer. |
Country Status (16)
Country | Link |
---|---|
US (3) | US20140227284A1 (es) |
EP (1) | EP2734199B1 (es) |
JP (1) | JP6270719B2 (es) |
KR (2) | KR20140072026A (es) |
CN (2) | CN103826623A (es) |
AU (2) | AU2012286542A1 (es) |
BR (1) | BR112014001430A2 (es) |
CA (1) | CA2842443C (es) |
DK (1) | DK2734199T3 (es) |
ES (1) | ES2937269T3 (es) |
IL (1) | IL230575B (es) |
MX (1) | MX368261B (es) |
PL (1) | PL2734199T3 (es) |
RU (1) | RU2665952C2 (es) |
SG (1) | SG10201605814QA (es) |
WO (1) | WO2013013302A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2734199T3 (pl) | 2011-07-22 | 2023-03-20 | Pacylex Pharmaceuticals Inc. | Syntetyczna letalność i leczenie nowotworów |
CN110974967B (zh) * | 2012-10-30 | 2023-11-07 | 厄尔莱克斯制药公司 | 合成致死与癌症的治疗 |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
WO2017011907A1 (en) | 2015-07-17 | 2017-01-26 | Pacylex Pharmaceuticals Inc. | Epigenetic silencing of nmt2 |
GB202017367D0 (en) * | 2020-11-02 | 2020-12-16 | Imperial College Innovations Ltd | Novel use |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2657259A1 (fr) * | 1990-01-25 | 1991-07-26 | Adir | Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. |
US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
CA2517629C (en) | 2003-03-12 | 2011-07-12 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
KR101138471B1 (ko) | 2003-07-25 | 2012-04-25 | 화이자 인코포레이티드 | 트리시클로 parp 저해제 |
CN1905864B (zh) | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
JP5545690B2 (ja) | 2003-12-01 | 2014-07-09 | クドス ファーマシューティカルズ リミテッド | 癌治療のためのdna損傷修復阻害剤 |
MXPA06008746A (es) | 2004-02-06 | 2007-01-23 | Elan Pharm Inc | Metodos y composiciones para tratamiento de tumores y enfermedad metastatica. |
ATE456579T1 (de) | 2004-07-20 | 2010-02-15 | Genentech Inc | Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung |
WO2006086043A2 (en) | 2004-11-23 | 2006-08-17 | Science & Technology Corporation @ Unm | Molecular technologies for improved risk classification and therapy for acute lymphoblastic leukemia in children and adults |
CA2623653C (en) * | 2005-09-27 | 2012-08-28 | University Of Saskatchewan | Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis |
EP2099305B1 (en) * | 2006-12-18 | 2015-07-15 | Jack L. Arbiser | Novel palladium complexes inhibit n-myristoyltransferase activity in vitro and cancer growth in vivo |
GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
PL2734199T3 (pl) | 2011-07-22 | 2023-03-20 | Pacylex Pharmaceuticals Inc. | Syntetyczna letalność i leczenie nowotworów |
CN110974967B (zh) | 2012-10-30 | 2023-11-07 | 厄尔莱克斯制药公司 | 合成致死与癌症的治疗 |
WO2017011907A1 (en) | 2015-07-17 | 2017-01-26 | Pacylex Pharmaceuticals Inc. | Epigenetic silencing of nmt2 |
-
2012
- 2012-07-23 PL PL12817041.2T patent/PL2734199T3/pl unknown
- 2012-07-23 CN CN201280046437.8A patent/CN103826623A/zh active Pending
- 2012-07-23 KR KR1020147004635A patent/KR20140072026A/ko not_active IP Right Cessation
- 2012-07-23 US US14/234,312 patent/US20140227284A1/en not_active Abandoned
- 2012-07-23 JP JP2014520475A patent/JP6270719B2/ja active Active
- 2012-07-23 BR BR112014001430A patent/BR112014001430A2/pt not_active Application Discontinuation
- 2012-07-23 DK DK12817041.2T patent/DK2734199T3/da active
- 2012-07-23 WO PCT/CA2012/000696 patent/WO2013013302A1/en active Application Filing
- 2012-07-23 ES ES12817041T patent/ES2937269T3/es active Active
- 2012-07-23 MX MX2014000661A patent/MX368261B/es active IP Right Grant
- 2012-07-23 AU AU2012286542A patent/AU2012286542A1/en not_active Abandoned
- 2012-07-23 RU RU2014101787A patent/RU2665952C2/ru active
- 2012-07-23 KR KR1020207020705A patent/KR102164964B1/ko active IP Right Grant
- 2012-07-23 SG SG10201605814QA patent/SG10201605814QA/en unknown
- 2012-07-23 CN CN201910130300.4A patent/CN110115768A/zh active Pending
- 2012-07-23 CA CA2842443A patent/CA2842443C/en active Active
- 2012-07-23 EP EP12817041.2A patent/EP2734199B1/en active Active
-
2014
- 2014-01-21 IL IL230575A patent/IL230575B/en unknown
-
2018
- 2018-04-24 AU AU2018202839A patent/AU2018202839B2/en active Active
- 2018-07-02 US US16/025,835 patent/US11135218B2/en active Active
-
2021
- 2021-10-01 US US17/492,427 patent/US20220023294A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018202839A1 (en) | 2018-05-10 |
IL230575A0 (en) | 2014-03-31 |
CA2842443A1 (en) | 2013-01-31 |
EP2734199A4 (en) | 2015-04-01 |
KR102164964B1 (ko) | 2020-10-14 |
WO2013013302A1 (en) | 2013-01-31 |
US20190000838A1 (en) | 2019-01-03 |
JP2014523440A (ja) | 2014-09-11 |
US20140227284A1 (en) | 2014-08-14 |
DK2734199T3 (da) | 2023-01-30 |
PL2734199T3 (pl) | 2023-03-20 |
ES2937269T3 (es) | 2023-03-27 |
CN110115768A (zh) | 2019-08-13 |
RU2014101787A (ru) | 2015-08-27 |
RU2665952C2 (ru) | 2018-09-05 |
EP2734199A1 (en) | 2014-05-28 |
US20220023294A1 (en) | 2022-01-27 |
WO2013013302A8 (en) | 2014-02-27 |
EP2734199B1 (en) | 2022-11-16 |
CN103826623A (zh) | 2014-05-28 |
CA2842443C (en) | 2022-01-25 |
AU2012286542A1 (en) | 2014-02-06 |
JP6270719B2 (ja) | 2018-01-31 |
SG10201605814QA (en) | 2016-09-29 |
IL230575B (en) | 2021-07-29 |
AU2018202839B2 (en) | 2020-04-09 |
US11135218B2 (en) | 2021-10-05 |
KR20200093065A (ko) | 2020-08-04 |
BR112014001430A2 (pt) | 2017-02-21 |
MX2014000661A (es) | 2014-09-08 |
KR20140072026A (ko) | 2014-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX369609B (es) | Una composición para usarse en el tratamiento de cáncer deficiente en nmt2. | |
PH12017502141A1 (en) | Compounds and their methods of use | |
PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
BR112013002012A2 (pt) | métodos e composições para terapia de câncer de fígado | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
MX2015006478A (es) | Inhibidores de glutaminasa y metodos de empleo. | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
MX2020004689A (es) | Tratamiento del cancer con inhibidores de tor cinasa. | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
MX2014011583A (es) | Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. | |
MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
PH12015501038A1 (en) | Inhibitors of iap | |
SG10201900564WA (en) | Methods for treating cancer | |
PH12015500867A1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
TN2014000086A1 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
MX368261B (es) | Letalidad sintetica y el tratamiento de cancer. | |
IN2014DN08385A (es) | ||
WO2012170742A3 (en) | Treatment and prevention of cancer with hmgb1 antagonists | |
TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
TN2013000247A1 (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |